What is Symbio Research?
Symbio Research operates as a high-authority Contract Research Organization (CRO) providing comprehensive, end-to-end clinical trial solutions. With a proven track record encompassing over 650 trials and 70 FDA approvals, the company serves as a critical partner for pharmaceutical and biotech sponsors. Their service portfolio spans clinical trial project management, regulatory affairs, and medical writing, all designed to streamline the path to market entry. By maintaining a focus on clinical excellence and proactive sponsor communication, Symbio Research has established itself as a reliable entity in the complex landscape of medical development and regulatory compliance.
How much funding has Symbio Research raised?
Symbio Research has raised a total of $1.4M across 1 funding round:
Debt
$1.4M
Debt (2021): $1.4M with participation from PPP
Key Investors in Symbio Research
PPP
Public-Private Partnership
What's next for Symbio Research?
With the recent influx of capital, Symbio Research is poised to scale its infrastructure to meet the growing demand for specialized clinical trial management. The strategic allocation of these funds will likely focus on enhancing their regulatory affairs division and expanding their reach in the inflammation and aesthetics markets. As the company continues to leverage its deep expertise, the focus will remain on optimizing trial timelines and maintaining the high standards of data integrity required for successful FDA submissions. This growth phase marks a pivotal transition toward broader enterprise-level service delivery.
See full Symbio Research company page
